Market news
Every market development we have covered, newest first.
4 dated market items. Most recent: Generic semaglutide launches abroad; US patients wait until 2031 (2026-08-06).
All-in monthly cost at 10 mg
What this beat covers
Who enters, who leaves, and who quietly stops dispensing. Departures matter more to a patient than launches, because a programme exiting mid-titration interrupts a course at the point where interruption is most costly.
We record an exit when the programme itself says so or when its own pages stop offering the product. We do not infer an exit from a competitor's claim, and we do not treat a temporary supply pause as a departure.
Stories in this category
Generic semaglutide launches abroad; US patients wait until 2031
Indian generics started near $8 a month in March. The FDA has tentatively approved a US version …
Ro and WeightWatchers Clinic now carry brand only
Two of the largest consumer platforms stopped selling compounded tirzepatide during 2026, with m…
Microdose protocols spread, and they are not comparable to standard dosing
Fractional-dose plans at lower prices do not map onto the 2.5–15 mg ladder every comparison uses…
Hims closes its compounded GLP-1 programme to new patients
Following a settlement with Novo Nordisk, one of the largest platforms exits compounded semaglut…
How to read a dated item
Every story carries the date we recorded it and links to what we read. Nothing here is undated, because an undated claim about a market that reprices this often is not usable. Where an item concerns a price, the figure is repeated with its dose and its fee basis attached rather than left to be inferred from the headline.
If an item is wrong, it gets a correction with a date rather than a silent edit. The full log is at corrections, and it includes errors we found in our own work.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.